Wisconsin Alumni Research Foundation

Technology

Novel Small Molecule SIRT6 Activators/Inhibitors

The epigenetic modifier SIRT6 is of the sirtuin class of proteins. In transgenic mice, increased SIRT6 expression lowers LDL and triglyceride levels, improves glucose tolerance and increases mitochond...
Learn More
John Denu, Weiping Tang | P160306US01

Technology

Synstatin “SSTNI/V” Disrupts Cancer Growth

Leading UW–Madison oncologists previously showed that the matrix receptor syndecan-1 (Sdc1/CD138) – a matrix receptor highly expressed in multiple myeloma – captures and activates multiple cell ...
Learn More
Alan Rapraeger, DeannaLee Beauvais, Oisun Jung | P160224US02

Technology

Compounds to Treat Hyperlipidemia and Fatty Liver Disease

Hyperlipidemia is a condition strongly associated with obesity and is an independent risk factor for the development of coronary heart disease. To help combat hyperlipidemia, the pharmaceutical indust...
Learn More
Mark Keller, Alan Attie, Sheldon Engelhorn, Nikolai Sepetov, Sergei Romanov, David Bernlohr | P110006US01

Technology

Enzyme Aids Intranasal Drug Delivery

Currently, delivering drugs directly into the brain requires invasive surgery. This is because a tight cellular layer called the blood-brain barrier (BBB) not only prevents harmful substances from ent...
Learn More
Robert Thorne, Jeffrey Lochhead | P120322US02

Technology

Use of Salate Derivatives to Treat Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease affecting 2.5 million people worldwide. The disease is difficult to manage and there is no cure. The underlying mechanism of MS pro...
Learn More
Hector DeLuca, Lori Plum, Steven Marling, Yanping Wang | P160384US02

WARF